Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Aug 15, 2013; 4(4): 151-156
Published online Aug 15, 2013. doi: 10.4239/wjd.v4.i4.151
Published online Aug 15, 2013. doi: 10.4239/wjd.v4.i4.151
Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes
Plamen Kozlovski, Novartis Pharma AG, CH-4002 Basel, Switzerland
James Foley, Qing Shao, Valentina Lukashevich, Wolfgang Kothny, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, United States
Author contributions: Kozlovski P drafted the manuscript and was critical to conducting the trial, initial data interpretation and overall clinical interpretation; Kothny W contributed to study design, initial data interpretation and overall clinical interpretation; Lukashevich V was critical to designing and conducting the trial, data collection and initial data interpretation; Shao Q was responsible for the statistical analysis; Foley J contributed to the overall data interpretation; all authors were involved in manuscript revisions and are responsible for intellectual content.
Supported by Novartis Pharma AG
Correspondence to: Plamen Kozlovski, MD, Novartis Pharma AG, CH-4002 Basel, Switzerland. plamen.kozlovski@novartis.com
Telephone: +41-61-6964697 Fax: +41-61-3247921
Received: March 28, 2013
Revised: May 11, 2013
Accepted: June 18, 2013
Published online: August 15, 2013
Revised: May 11, 2013
Accepted: June 18, 2013
Published online: August 15, 2013
Core Tip
Core tip: In Asian patients, vildagliptin added to stable dose of insulin, with or without concomitant metformin, significantly improves glycemic control without increase in weight and hypoglycemia incidence.